Recent studies have focused on the intersection of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and DA signaling. While GIP activators are commonly employed for addressing type 2 diabetes, their emerging consequences on reinforcement circuits, specifically influenced by dopamine networks, are receiving sig… Read More